Marcia S. Brose, MD, PhD | Authors

August 31, 2015

Marcia S. Brose, MD, PhD, discusses the SELECT trial, which looks at lenvatinib for patients with 131I-refractory differentiated thyroid cancer.

May 31, 2015

Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses the effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in the SELECT trial.

November 22, 2014

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center at the University of Pennsylvania, discusses next-generation sequencing in thyroid cancer.

September 27, 2014

Marcia S. Brose, MD, PhD, discusses using both sorafenib and lenvatinib as treatment options for thyroid cancer.

July 09, 2014

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discusses the tolerability and safety of sorafenib as seen in patients with thyroid cancer.

June 06, 2014

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discusses the updated overall survival analysis of the phase III DECISION trial, which looked at sorafenib for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC).